CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D008457: Measles NIH

(Synonyms: Me, Measles)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug1697 Measles-Mumps-Rubella Vaccine Wiki 0.58
drug621 Case fatality rate Wiki 0.58
drug2176 Placebos Wiki 0.14

Correlated MeSH Terms (0)


Name (Synonyms) Correlation

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There are 3 clinical trials

Clinical Trials


1 Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)

Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is that cross-protective antibodies against measles vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV, The primary objective of the present study is to determine the benefit of measles vaccine in health care professional to decrease the incidence of COVID-19. We Hypothesized that, measles vaccine may lower the incidence of serologically proven SARS-CoV-2 infection and reported respiratory illness

NCT04357028 Covid19 Drug: Measles-Mumps-Rubella Vaccine Drug: Placebos
MeSH:Measles

Primary Outcomes

Description: Number of participants with asymptomatic or mild COVID-19 disease defined as fever (using self-reported questionnaire), plus at least one sign or symptom of respiratory disease including cough, runny/blocked nose (using self-reported questionnaire), plus positive SARS-Cov-2 test (PCR or serology)

Measure: COVID-19 disease incidence

Time: Time Frame: Measured over the 6 months following randomization

Secondary Outcomes

Description: Number of pneumonia cases (abnormal chest X-ray) (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test

Measure: SARS-CoV-2 pneumonia

Time: Time Frame: Measured over the 6 months following randomization

Description: Number of days admitted to critical care (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test

Measure: Critical care admission duration with SARS-CoV-2

Time: Time Frame: Measured over the 6 months following randomization

Description: Need for oxygen therapy (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test

Measure: Oxygen therapy with SARS-CoV-2

Time: Time Frame: Measured over the 6 months following randomization

2 Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?

The following two mechanisms that explain the ability of measles vaccine to cause partial protection against COVID-19. The first is that measles vaccine may increase the ability of the immune system to fight off pathogens other than measles due to the generated bystander immunity that would enhance the overall immunity against the new coronavirus. The second is that SARS-CoV-2 is proven to have structure similarities with measles, which may cause cross-reactivity and immunity between measles vaccines and COVID-19, leading to partial protection against COVID-19 in vaccinated subjects

NCT04445610 Coro Coronavirus (COVID-19)
MeSH:Measles

Primary Outcomes

Description: Achievement of two consecutive negative PCR results for COVID 19 and discharge from hospital

Measure: Viral clearance

Time: 6 months

3 Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by SARS CoV-2 in OECD Countries?

Mortality rates caused by SARS CoV-2 differ between countries and this difference might be explained by several reasons. Childhood vaccination rate is thought to be one of them. Therefore present study aimed to examine the possible relationship between DTaP (diphtheria, tetanus, pertussis) and measles vaccination rates of Organization for Economic Co-operation and Development (OECD) countries and case fatality rate (CFR) caused by SARS CoV-2.

NCT04468802 Covid19 Measles Vaccine Mortality Other: Case fatality rate
MeSH:Measles

Primary Outcomes

Description: Mortality rate caused by SARS CoV-2

Measure: Case Fatality Rate

Time: 4 months


HPO Nodes